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Objective. To investigate whether advanced glycation endproducts (AGEs) in the skin are increased in patients with systemic
sclerosis (SSc) and are related to the presence of disease-related and traditional cardiovascular risk factors. Methods.S k i n
autoﬂuorescence, as a measure for the accumulation of AGEs, was assessed by measuring UV-A light excitation-emission matrices
(AF-EEMS) in 41 SSc patients and 41 age- and sex-matched controls. Traditional cardiovascular risk factors and disease-related
risk factors were recorded. Results. Skin AF-EEMS did not diﬀer between SSc patients and controls (1.68 ± 0.58a.u. versus
1.63 ± 0.41a.u., P = 0.684). Skin AF-EEMS in SSc patients was associated with levels of CRP (r = 0.44, P = 0.004), Medsger’s
severity scale (r = 0.45, P = 0.006), and use of agents intervening in the renin-angiotensin system (r = 0.33, P = 0.027).
When analysing SSc patients and controls together, in multivariate analysis, only age and use of agents intervening in the renin-
angiotensin system were independently associated with AF-EEMS. Conclusion. These data demonstrate that skin AGEs are not
increased in SSc patients.
1.Introduction
Vascular involvement is a key factor in major manifestations
of systemic sclerosis (SSc), such as Raynaud’s phenomenon
(RP), myocardial dysfunction, pulmonary hypertension, and
renal involvement. Microvascular involvement, in which
endothelial injury is present, is the main characteristic of
SSc [1, 2] Oxidative stress has been suggested as a major
player in the process of endothelial dysfunction found in
SSc. Endothelial damage may be induced by oxygen free
radicals and reactive nitrogen species, generated locally
by the inﬂammatory process and by periods of tissue
ischemia followed by postischaemic reperfusion. This so-
called ischaemic-reperfusion injury can be seen in RP [3, 4].
Increased levels of antibodies against oxidised low-density
lipoproteins (LDL) [4–6] and increased serum levels of 8-
isoprostane [7], being markers of oxidative stress, have,
indeed, been observed in SSc.
Oxidative or carbonyl stress, leading to formation of
so-called reactive carbonyl compounds, is an important
source for the generation of so-called advanced glycation
endproducts (AGEs) [8]. AGE generation as a result of
oxidativestresshasalsobeenfoundininﬂammatorydiseases,
such as rheumatoid arthritis and SLE [9–15].
Tissue autoﬂuorescence (AF) is a marker of the accu-
mulation of AGEs, validated in diﬀerent patient groups
and healthy controls [16–18]. Therefore, we assessed AGE
accumulation in patients with SSc and hypothesized that2 International Journal of Rheumatology
AGE accumulation is increased in patients with SSc com-
pared to healthy controls based on the presence of oxidative
stress and endothelial dysfunction in SSc. We related AGE
accumulation to the presence of disease-related and tradi-
tional cardiovascular risk factors.
2.MaterialandMethods
2.1. Patients. Forty-one patients with limited cutaneous SSc
from our university medical center out-patient clinic, fulﬁll-
ing the ACR criteria for SSc [19] were included. Exclusion
criterium was pregnancy. Forty-one age- and sex-matched
healthysubjectswererecruitedascontrols.Thelocalresearch
ethics committee gave approval for the study, and informed
consent was obtained from all subjects. Clinical data were
obtained by chart review and questionnaires. Diabetes
mellitus was deﬁned by the criteria from the American
Diabetes Association. Dyslipidemia was diagnosed if plasma
cholesterol exceeded 6.21mmol/L, LDL cholesterol exceeded
3.36mmol/L, and triglycerides exceeded 2.26mmol/L or
when the patient used lipid-lowering drugs [20]. Hyper-
tension could not be categorized because of frequent use
in SSc patients of vasodilating agents, such as calcium
channel antagonists and ketanserin for other reasons than
hypertension. Creatinine clearance (CrCl) was estimated
usingtheCockcroft-Gaultformula.Smokingstatusandbody
mass index were also recorded. The SCORE risk estimation
system was used, which was originally developed to obtain
an estimation of total 10-year fatal cardiovascular risk in
populations,usinggender,age,totalcholesterollevel,systolic
blood pressure, and smoking status [21]. Furthermore, we
assessed disease-related factors that might inﬂuence skin AF
and the development of atherosclerosis. Modiﬁed Rodnan
Skin Score was assessed to determine skin thickness. To
assess disease activity the preliminary European Scleroderma
Study Group (EScSG) activity indices (a score ranging
from 0 to 10) [22, 23] and the revised preliminary SSc
severity scale (Medsger’s severity scale) [24]w e r eu s e d .
Immunosuppressive therapy was recorded.
2.2. Assessment of Skin AF. Tissue AGEs accumulation can
be assessed as skin autoﬂuorescence (AF), following the
principles of the AGE Reader, which is a validated and
noninvasive technique [16, 25]. Repeated measurements
on one day in controls and diabetic patients showed an
overall Alman error percentage of 5%. In this study, an
adapted setup of the AGE Reader was used, namely, the
Excitation Emission Matrix Scanner (EEMS), which is a
technique to determine skin autoﬂuorescence (AF-EEMS),
which has the additional potential to discriminate between
autoﬂuorescence spectra from diﬀerent ﬂuorophores. This
technique and setup has been described [26]. Measurement
was performed at a skin site of approximately 4cm2 without
evidence of ﬁbrosis at the ventral site of the forearm, or
other skin lesions. A series of measurements was obtained
for each subject, and mean skin AF-EEMS was determined
as described [14]. Skin pigmentation is also known to
inﬂuence autoﬂuorescence by light absorption. Therefore
skin reﬂection should be >10% to perform an adequate
measurement.
2.3. Laboratory Assessments. Lipid concentrations (total,
high density lipoprotein (HDL) and low-density lipoprotein
(LDL) cholesterol and triglycerides), glucose, and creatinin
were measured by routine techniques. CRP was mea-
sured using in-house enzyme-linked immunosorbent assays
(ELISAs) as described [27].
2.4. Statistical Analysis. V a l u e sa r ee x p r e s s e da sm e a n±
SD when variables were normally distributed. In case of
a nonnormal distribution, values are reported as median
(interquartile ranges). For comparison between groups, con-
tinuous variables were analysed by Student’s t-test or Mann-
Whitney U tests, as appropriate. In case of categorical vari-
ables,thechi-squaretestwasused.Theunivariatecorrelation
between AF-EEMS values and other categorical variables was
assessedbyPearson’scorrelationcoeﬃcientincaseofnormal
distribution. Otherwise, Spearman’s correlation coeﬃcient
was used. To assess the inﬂuence of tested parameters mul-
tiple regression analysis using the backward method was
performed to assess the inﬂuence of demographic variables,
outcome variables, and disease-related factors on skin aut-
oﬂuorescence(AF-EEMS).Variableswhichweresigniﬁcantly
correlated in univariate analysis were used as independent
variables in the multivariate analysis.
A l la n a l y s e sw e r ep e r f o r m e du s i n gS P S S1 4 . 0 .At w o -
tailed P value < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Characteristics of Patients and Controls. Characteristics
of patients and controls are presented in Tables 1 and 2.
Patients and controls were similar in age and gender and
regarding (family) history of CVD, presence of diabetes
mellitus, and renal function. Signiﬁcant diﬀerences between
SSc patients and controls were present in diastolic blood
pressureandlipidlevels,butalsoinmedicationused.Antihy-
pertensive agents or vasodilating agents were used in 80% of
patients compared to 2% of controls. Amongst these agents,
11 patients used angiotensin-converting enzyme (ACE)
inhibitors and 3 patients used an angiotensin II receptor
blocker. Also, statins were used more frequently in patients.
BMI was slightly higher in controls, and none of the controls
had a history of cardiovascular disease. Although the pres-
ence of traditional risk factors diﬀered signiﬁcantly between
patients and controls, the total cardiovascular risk, SCORE,
was comparable. CRP levels were signiﬁcantly increased
in patients compared to controls (3.4mg/L (IQR 1.7–7.7)
versus 1.4mg/L (0.6–2.5), P<0.001). Immunosuppressive
agents, such as prednisolone, methotrexate, azathioprine,
and cyclophosphamide were used in 15 (37%) SSc patients.
3.2. Skin AF-EEMS in Patients and Controls. No diﬀerence
was found in AF-EEMS between patients and healthy
controls (1.68 ± 0.58a.u. versus 1.63 ± 0.41a.u., P = 0.684,
Figure 1). AF-EEMS was signiﬁcantly higher in those withInternational Journal of Rheumatology 3
Table 1: Clinical characteristics.
Patients (n = 41) Controls (n = 41) P values
Age (years) 55.9 ± 11.0 55.4 ± 9.0 NS
Female, n (%) 33 (80%) 33 (80%) NS
History of CVD, n (%) 4 (9%) 0 NS
Family history of CVD, n (%) 9 (22%) 13 (32%) NS
Diabetes mellitus, n (%) 2 (5%) 0 NS
Glucose (mmol/L) 4.9 (4.3–5.4) 5.6 (5.3–6.2) <0.001
BMI (kg/m2) 24.1 (21.1–25.3) 25.0 (22.2–27.1) 0.019
Creatinine (μmol/L) 80 (67–93) 77 (59-84) NS
Creatinine clearance (mL/min/1.73m2)7 8 ± 23 87 ± 14 NS
Current smoking 3 (7%) 0 NS
Blood pressure
Systolic (mmHg) 120 (11–138) 128 (118–140) NS
Diastolic (mmHg) 75 (70–80) 78 (72–87) 0.023
Antihypertensive or vasodilating agents 33 (80%) 1 (2%) <0.001
ACE inhibitors or ATII receptor blockers 14 (34) 1 (2%) <0.001
Lipid levels
Cholesterol (mmol/L) 5.0 ± 0.9 5.8 ± 0.9 <0.001
HDL cholesterol (mmol/L) 1.3 (1.2–2.2) 1.7 (1.4–2.0) 0.025
LDL cholesterol (mmol/L) 2.9 ± 0.8 3.5 ± 0.8 0.001
Triglycerides (mmol/L) 1.4 (1.2–2.2) 1.2 (0.9–1.7) 0.035
Statin use 7 (17%) 0 0.012
Dyslipidemia, n (%) 18 (44) 19 (46) NS
Aspirin use 12 (29%) 0 <0.001
SCORE, % 1.0 (0.0–2.0) 1.0 (0.0–2.0) NS
CRP (mg/L) 3.4 (1.6–7.7) 1.5 (0.6–2.5) <0.001
Unless stated otherwise, data are expressed as mean ± SD when normally distributed and as median (25–75%) when nonnormally distributed.
CVD: cardiovascular disease; BMI: body mass index; ACE: angiotensin-converting enzyme; ATII: angiotensin II; HDL: high-density lipoprotein; LDL:l o w -
density lipoprotein; SCORE: systematic coronary risk evaluation; CRP: C-reactive protein.
Table 2: Disease characteristics and disease-related factors in SSc
patients.
Characteristic Patients, n (%)
Duration SSc, yr 5 (3–11)
Duration RP, yr 11 (5–23)
EScSG activity index 0.5 (0.5–2.0)
MSS 6 (5–7)
mRSS 7 (5–14)
Data are expressed as median (interquartile ranges).
SSc: systemic sclerosis; RP: Raynaud’s phenomenon; EscSG: European
Scleroderma Study Group; MSS: Medsger’s severity scale; mRSS: modiﬁed
Rodnan Skin Score.
a history of CVD (n = 4) compared to those without a
history of manifest CVD (n = 77) (2.22 ± 0.81a.u. versus
1.62±0.47a.u., P = 0.020). In subjects using ACE inhibitors
or ATII receptor blockers for hypertension or other reasons,
AF-EEMS was signiﬁcantly higher than in subjects not using
these agents (2.01 ± 0.62a.u. versus 1.57 ± 0.45a.u., P =
0.002).
Univariate analysis between skin AF-EEMS and tradi-
tional risk factors and disease-related factors for CVD in
SSc patients resulted in a positive correlation between skin
AF-EEMS and CRP (r = 0.44, P = 0.004), as well as MSS
(r = 0.45, P = 0.006) and use of ACE inhibitors or ATII
receptor blockers (r = 0.33, P = 0.027). Univariate analysis
of all subjects, patients and controls together, resulted in
an association between skin AF-EEMS and age (r = 0.28,
P = 0.010), CRP (P = 0.25, P = 0.026), and use of ACE
inhibitors or ATII receptor blockers (r = 0.275, P = 0.013).
All other clinical and biochemical variables did not show
signiﬁcant correlations with skin AF-EEMS.
Multivariate analysis revealed that age and use of ACE
inhibitors or ATII receptor blockers were independently
associated with skin AF-EEMS. Otherwise, no independent
associations with skin AF-EEMS were present (Table 3).
4. Discussion
In this study, we demonstrated that skin AF as a marker of
tissue AGE accumulation is not increased in SSc patients,
while expected relations with age, prevalence of CVD, and
CRP were found.
To our knowledge, only one study has been performed
on the relation between AGEs and SSc. Kaloudi et al. [28]
compared circulating levels of Nε-(carboxymethyl)lysine
(CML), one of the AGEs which can be detected in vivo, in4 International Journal of Rheumatology
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Figure 1: Skin autoﬂuorescence (AF-EEMS) in patients (closed
circles) and controls (open circles). The horizontal line represents
mean skin AF-EEMS values.
Table 3: Multiple linear regression analysis with AF-EEMS as
dependent variable in patients with systemic sclerosis and healthy
controls (n = 82).
B βP values
Constant 0.284
Age 0.022 .400 0.006
Use of ACE inhibitors or ATII
receptor blockers 0.613 .494 0.001
AF-EEMS: autoﬂuorescence obtained by the Excitation-Emission Matrix
Scanner; ACE: angiotensin-converting enzyme; ATII: angiotensin II.
SSc patients and healthy controls by means of ELISA. They
found increased CML levels in SSc patients regardless of
subset, with highest the levels found in SSc patients with
an “early” disease pattern in nailfold videocapillaroscopy,
suggesting that AGEs are involved in SSc microangiopathy.
This is in agreement with the observation that the highest
values of markers of oxidative stress are seen in early stages
of the disease [4].
Several factors may be responsible for this discrepancy.
We used noninvasive skin autoﬂuorescence measurements
for the assessment of accumulation of AGEs. This tech-
nique is simple, rapid, and noninvasive. Results from this
technique were found to correlate strongly with levels of
AGEs measured from skin biopsies [16, 29], although this
validation was not extended to patients with SSc. Also, AGE
detection in tissue with long-lived (years) proteins like the
skin may better reﬂect the chronic accumulation of AGEs
than measuring AGEs from serum or plasma with a relatively
short (weeks) half-life of most proteins [25]. Since disease
activity in SSc patients will wax and wane, we considered
noninvasive skin autoﬂuorescence measurements more use-
fulinthesepatients.Ourchoicefortheskinautoﬂuorescence
was also supported by the increased levels found in other
autoimmune diseases with intermittent disease activity like
rheumatoid arthitis and SLE in which skin AF was related
to integrated disease duration and damage [14, 15]. Another
consideration might be that skin AF was aﬀected in the
same emission range by other ﬂuorophores (like NADH or
tryptophan) to a diﬀerent extent than in other conditions.
Although we cannot exclude this, the expected relations with
factors like age, CRP, and history of CVD still support skin
AF as a marker of AGEs.
We expected to ﬁnd more AGE accumulation in SSc
patients with signs of inﬂammation and disease severity.
Compared to controls, we found higher CRP levels in SSc
patients, which might suggest a more active disease although
absolute levels were not increased and EscSG activity index
did not reﬂect active disease. We found a positive correlation
between skin AF-EEMs levels and MSS, a measure of activity,
severity, and damage in SSc patients, suggesting a relation
between AGE accumulation and disease severity. Recently,
doubts have been raised by Valentini and Cerinic on the
weighting of the contribution of the diﬀerent organ systems
in the MSS [30]. Perhaps such a disbalance in the MSS
explains why MSS, and also CRP, were not found to remain
as predictors of skin AF-EEMS in multivariate analysis.
We found higher skin AF-EEMS levels in a substantial
number of subjects using ACE inhibitors or ATII antagonists
compared to subjects not using these agents, and their use
was independently associated with skin AF-EEMS in multi-
variate analysis. This seems surprising because these agents
have been found to reduce AGE accumulation in animal
studiesandinvitrostudies[31–35].InourSScpatients,these
agents were used for a long period for several reasons, such
as hypertension and Raynaud’s phenomenon. Therefore,
this treatment would have been expected to diminish AGE
accumulation. We found higher skin AF-EEMS levels in
subjects using these agents, but it cannot be ruled out that
AGE accumulation was even more pronounced before agents
intervening in the renin-angiotensin system were used.
Skin ﬁbrosis in SSc could be a possible explanation
of the lack of increase in AF-EEMS values that we had
expected to occur, although we only included patients with
limited cutaneous SSc, who had no signiﬁcant ﬁbrosis of the
forearm. AGE accumulation and skin autoﬂuorescence are
strongly related to collagen-linked ﬂuorescence and, thereby,
to the usually very long half-time (15–20 years) of collagen.
Previously reported increases in both collagen synthesis but
especially increased degradation of skin collagen in SSc
suggest that our results in SSc patients may be explained
by accelerated skin collagen turnover [36–40]. In that case,
the accelerated degradation of skin collagen could have
prevented skin AGE accumulation and masked the eﬀects
of oxidative stress on AGE formation. Although assessment
of skin AF-EEMS was performed at visible and palpable
nonlesional skin to prevent inﬂuences by the presence of skin
ﬁbrosis, this inﬂuence cannot be ruled out completely. Also,
increased collagen turnover may not be limited to aﬀected
skin only.International Journal of Rheumatology 5
In conclusion, although oxidative stress seems present
in SSc and is an acknowledged important factor in the
generation of AGEs, increased levels of AGEs, as determined
by skin autoﬂuorescence, were not found. We cannot rule
out that accumulation of AGEs in SSc patients was prevented
by the use of ACE inhibitors or ATII receptor blockers, and
by accelerated skin collagen turnover in clinically unaﬀected
areas.
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